RE: Great news - in a nutshell!19 Nov 2025 09:27
Good review lionel,
"POC testing using Genedrive* CYP2C19 ID Kit significantly reduced the turnaround time for genotyping results. This resulted in patients being on optimal treatment faster, potentially reducing the risk of exposure to recurrent stroke or TIA, testing is more valuable in TIA clinics compared to a stroke inpatient setting as clopidagrel is first line treatment for TIAs as opposed to aspirin for stroke"